The National Health Surveillance Agency (Anvisa) announced the selection of new pharmaceutical projects for its regulatory advisory initiative. The program aims to guide pharmaceutical companies through the development and registration stages of new drugs, facilitating the path to regulatory approval.
The initiative represents an effort by Anvisa to modernize its interaction processes with the pharmaceutical industry, offering specialized technical support to drug developers. Through regulatory advisory, the agency provides guidance on requirements, necessary documentation, and development strategies aligned with Brazilian legislation.
This type of program is fundamental for accelerating pharmaceutical innovation in the country, allowing companies, especially startups and smaller industries, to better understand regulatory criteria before making significant investments in clinical development.
The selection of projects considered technical and scientific criteria, prioritizing medicines with innovative potential and relevance to Brazilian public health. Approved projects will receive continuous guidance from Anvisa during their development phases, from pre-clinical studies to the submission of registration requests.
The initiative consolidates Anvisa's commitment to promoting a clear and predictable regulatory environment, facilitating technology transfer and the development of new pharmaceutical solutions. By guiding applicants on technical and regulatory requirements from the initial phases, the agency helps increase process efficiency and reduce potential rework during registration analysis.
